686 results on '"Glover, Sarah"'
Search Results
152. Mepolizumab does not alter the blood basophil count in severe asthma
153. STAT3 Genotypic Variant rs744166 and Increased Tyrosine Phosphorylation of STAT3 in IL-23 Responsive Innate Lymphoid Cells during Pathogenesis of Crohn’s Disease
154. Su1832 – Inhibition of Intestinal Epithelial Cell Pyroptosis and Associated Mucosal Barrier Defects is a Potential Therapeutic Mechanism of Action for Mesalamine in Ibd
155. 535 – Ileal Biopsy Epithelial Cell Pyroptosis Predicts Clinical Response to Vedolizumab Therapy in Crohn's Disease
156. 415a – Anti-Tumor Necrosis Factor Therapy is Not Associated with Post-Operative Infection: Results from Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Postoperative Infection I (Puccini)
157. Mast Cells in Patients with Hereditary α-Tryptasemia Promote HLA-DR Expression and a Th2-Polarizing Microenvironment in the Gastrointestinal Tract
158. Tu1845 – Identification of a Unique Population of Gi Mast Cells in a Subset of Patients with Mast Cell Activation Syndrome
159. P128 INHIBITION OF INTESTINAL EPITHELIAL CELL PYROPTOSIS AND ASSOCIATED MUCOSAL BARRIER DEFECTS IS A POTENTIAL THERAPEUTIC MECHANISM OF ACTION FOR MESALAMINE IN IBD
160. P087 ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN’S DISEASE
161. P128 INHIBITION OF INTESTINAL EPITHELIAL CELL PYROPTOSIS AND ASSOCIATED MUCOSAL BARRIER DEFECTS IS A POTENTIAL THERAPEUTIC MECHANISM OF ACTION FOR MESALAMINE IN IBD
162. P087 ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN’S DISEASE
163. A mixing heteroduplex mobility assay (mHMA) to genotype homozygous mutants with small indels generated by CRISPR-Cas9 nucleases
164. The extracellular matrix microtopography drives critical changes in cellular motility and Rho A activity in colon cancer cells
165. Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease.
166. A distinct ecotonal tree community exists at central African forest–savanna transitions.
167. The NICE MEDLINE and Embase (Ovid) health apps search filters: development of validated filters to retrieve evidence about health apps.
168. Escherichia coli O157: H7 sepsis following fecal microbiota transplant in an IgA-deficient inflammatory bowel disease patient.
169. Prospective Evaluation of the Impact of Gastroenterological Manifestations on Length of Stay and Survival in Critically III COVID-19 Patients in Mississippi.
170. Small Bowel Pyogenic Granuloma With Cytomegalovirus Infection in a Patient With Crohn's Disease (Report of a Case and Review of the Literature)
171. CD117+ Exosomes and Mast Cells From Hereditary Alpha Tryptasemia Patients Reveal Unique Phosphorylation, Lipidomics, and Proteomics Profiles: Category Award (Small Intestine): Presidential Poster Award
172. Changes in urinary biomarkers between stable state and exacerbation of COPD
173. Pre-operative total parenteral nutrition improves post-operative outcomes in a subset of Crohn’s disease patients undergoing major abdominal surgery
174. Effects of Preoperative Use of Biologic Agents on Operative Outcomes in Crohn's Disease Patients
175. Quantitative assessment of intestinal stiffness and associations with fibrosis in human inflammatory bowel disease
176. 680 - Development of an Objective Prediction Model for Prolonged Postoperative Length of Stay in Crohn's Disease Patients Undergoing Major Abdominal Surgery
177. Su1865 - The Epidemiology and Economic Health Burden of the College-Aged IBD Population
178. Increased NKp44 (−) ILC3s in the peripheral blood of patients with Crohn’s disease
179. Mo1890 - Effects of Pre-Operative use of Biologic Agents on Intraoperative Blood Loss, Operative Time and Length of small Bowel Resection in Patients with Crohn's Disease
180. Innate lymphoid cell composition shift upon Campylobacter jejuni induced colitis, a process inhibited by targeting mTOR signaling in Il10−/− mice
181. Tu1816 - Potential Involvement of Stat3 Rs744166 in Crohn's Disease Pathogenesis
182. Mo1913 - Impact of Parenteral Nutrition on Postoperative Outcomes in Crohn's Disease Patients Undergoing Major Abdominal Surgery
183. Analysis of novel domain-specific mutations in the zebrafishndr2/cyclopsgene generated using CRISPR-Cas9 RNPs
184. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
185. P177 EFFECTS OF PRE-OPERATIVE USE OF BIOLOGIC AGENTS ON INTRA-OPERATIVE BLOOD LOSS, OPERATIVE TIME AND LENGTH OF SMALL BOWEL RESECTION IN CROHN’S DISEASE PATIENTS
186. Critical Essays on William Faulkner.
187. Secondary Chemistry School Teachers working in tertiary education Chemistry Departments; critical reflections on the positives and negatives
188. Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
189. Why do Secondary School Chemistry Teachers Engage in Long-Term Outreach Partnership with a University?
190. All IBD is Not Necessarily Sporadic IBD; A Case of Primary Immunodeficiency Mimicking Small Bowel Crohnʼs Disease
191. Oesophageal mastocytosis: eosinophilic oesophagitis without eosinophils?
192. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis
193. Successful targeted treatment of mast cell activation syndrome with tofacitinib
194. Increased NCR negative ILC 3 may be indicative for the early development of spontaneous colitis in the IL 10 knockout mouse
195. Tu1307 Impact of Chromoendoscopy on Outcomes in Inflammatory Bowel Disease Patients With a History of Low Grade Dysplasia on White-Light Endoscopy
196. Impaired AHR Signaling Contributes To Intestinal ILC3/ILC1 Conversion In The Inflamed Terminal Ileum Of Crohn’s Disease Patients
197. Comparative Persistence of Biologics in the Treatment of Inflammatory Bowel Disease: A Truven Marketscan Database Study
198. Pyroptosis of Intestinal Epithelial Cells is Crucial to the Development of Mucosal Barrier Dysfunction and Intestinal Inflammation
199. The Incorporation of Medical Scribes into an Academic IBD Clinic Improved Clinical Efficiency, Quality of Care, and Patient Satisfaction
200. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.